13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Cognitive Neuropsychology
Cognitive neuropsychology serves as a dynamic crossroads where cognitive psychology intertwines with neuroscientific principles, seeking to untangle the intricate interplay between brain function and cognitive processes. Its mission encompasses a deep exploration of how the brain's structures and networks contribute to a myriad of cognitive functions, spanning attention, memory, language, perception, and executive functions. This discipline meticulously scrutinizes individuals with specific brain lesions, injuries, or neurodevelopmental disorders, dissecting resulting cognitive deficits to unveil invaluable insights into the neural foundations of cognition. Leveraging an array of research methodologies, from traditional behavioral experiments to cutting-edge neuroimaging techniques like functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), and event-related potentials (ERPs), cognitive neuropsychologists strive to illuminate the intricate neural circuits and mechanisms underpinning cognition.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States